Lee S. Schwartzberg, MD, FACP

Profession: Senior Partner and Medical Director, The West Clinic, Memphis, TN
Member since: 2006 Dec 18

Recent Posts

Dr. Lee Schwartzberg: Bone-Targeted Agents Were Last Year's Top Story in Supportive Care

Interview by L Scott Zoeller. 2012 Jan 18, Lee Schwartzberg, MD

Chemotherapy + Cetuximab Improves Survival in EGFR-Expressing NSCLC

Lancet Oncol. 2012 Jan 1;[Epub Ahead of Print], R Pirker, et al

Bevacizumab Effective With First-Line Treatment for Ovarian Cancer

Elsevier Global Medical News. 2012 Jan 4, MA Moon

Pertuzumab Added to Trastuzumab/Docetaxel Benefits Metastatic Breast Cancer

N Engl J Med. 2011 Dec 7;[Epub Ahead of Print], J Baselga, et al

Denosumab and Bone–Metastasis-Free Survival In Advanced Prostate Cancer

Lancet. 2011 Nov 15;[Epub Ahead of Print], MR Smith, et al

Mechanism of Sorafenib-Induced Skin Tumors Proposed

Clin Cancer Res. 2011 Nov 17;[Epub Ahead of Print], JP Arnault, et al

OS Benefit With Letrozole After 5-Year Tamoxifen

J Clin Oncol. 2011 Oct 31;[Epub Ahead of Print], H Jin, et al

SNPs Associated With Safety and Efficacy in Sunitinib-Treated Kidney Cancer

Lancet Oncol. 2011 Oct 18;[Epub Ahead of Print], J Garcia-Donas, et al

Intraoperative MRI Guidance Beneficial in Glioma Resection

Lancet Oncol. 2011 Aug 23;[Epub Ahead of Print], C Senft, et al

Clinical Advances From the World Congress on Lung Cancer

2011 Aug 17, Lee Schwartzberg, MD, Editor-in-Chief

Take-Home Messages—The 6th Annual Community Oncology Conference

2011 Apr 26, Lee Schwartzberg, MD, Editor-in-Chief

EGFR Testing Necessary for All Patients With NSCLC

J Clin Oncol. 2011 Apr 11;[Epub Ahead of Print], SP D'Angelo, et al

FDA Approves First Drug for Medullary Thyroid Cancer

Elsevier Global Medical News. 2011 Apr 6, E Mechcatie

Anti-Emesis: IV Fosaprepitant Noninferior to Oral Aprepitant

J Clin Oncol. 2011 Mar 7;[Epub Ahead of Print], S Grunberg, et al

Eribulin Improves Survival in Metastatic Breast Cancer

Lancet. 2011 Mar 3;[Epub Ahead of Print], J Cortes, et al

Dr. Lee Schwartzberg: Health Care Reform Will Transform Virtually Every Aspect of Cancer Care

Top Stories of 2010. 2011 Jan 18, Interview by L Scott Zoeller

Iniparib + GC Effective in Metastatic Triple-Negative Breast Cancer

N Engl J Med. 2011 Jan 5;[Epub Ahead of Print], J O’Shaughnessy, et al

Trastuzumab-DM1 Is Effective in Pre-treated HER2+ Metastatic Breast Cancer

J Clin Oncol. 2010 Dec 20;[Epub Ahead of Print], HA Burris III, et al

Drs. Lee Schwartzberg and David Henry Provide Scientific Highlights From Day 1

Linda Bosserman for the OncologySTAT Editorial Team. 2008 Feb 12
Read More

Bio

Biographical Sketch: 
Dr. Schwartzberg is a senior partner and Medical Director of the West Clinic, a 30-physician practice specializing in oncology, hematology and radiology located in Memphis, TN. He completed his fellowship training in medical oncology and hematology at Memorial Sloan-Kettering Cancer Center, where he also served as Chief Medical Resident and was a founding member of the institutional ethics committee. 

Dr. Schwartzberg is a Clinical Professor of Medicine at the University of Tennessee College of Medicine. He is founder and Medical Director for the Baptist Centers for Cancer Care Cancer Genetics Program and the Stem Cell Transplant Program. He also serves as the chair of the Baptist Comprehensive Breast Center multidisciplinary program. He is the founding editor-in-chief of Community Oncology and serves on the editorial board of the Journal of Supportive Oncology

In addition to maintaining a private practice in medical oncology, Dr. Schwartzberg spends a significant portion of time devoted to oncology clinical trial development and execution, authoring more than 60 peer-reviewed research papers. His major research interests are new therapeutic approaches to breast cancer, targeted therapy, and supportive care. Dr. Schwartzberg was the principal investigator for the Baptist Cancer Institute CCOP from 1995 to 2000. Since then he has focused his research interests as President and Chief Medical Officer of the Accelerated Community Oncology Research Network (ACORN).

Positions: 
Medical Director, The West Clinic, Memphis, TN
Clinical Professor of Medicine, University of Tennessee College of Medicine, Memphis, TN

Degrees: 
State University of New York, BA and MS 
New York Medical College, MD, FACP 

Postgraduate Training: 
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center

Board Certifications: 
Medical oncology 
Hematology 

Clinical Interests: 
Medical oncology/hematology 

Comment Print page RSS feeds

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for one or more of our leading newsletters -- delivered weekly to your inbox.

Advisory and Editorial Boards

Meet OncologySTAT's Advisory and Editorial Boards that represent community practitioners and academic specialists with cross-disciplinary expertise.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration